Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, phase II study, comparing the efficacy and safety of
trastuzumab plus aromatase inhibitors, with or without pyrotinib, in the treatment of HR
(hormone receptor)+/HER2 (human epidermal growth factor receptor 2) + MBC and inoperable LABC
patients.